Two of three judges on a federal appeals court panel strongly indicated this morning that they reject the federal government’s position that nothing in the 340B statute gives drug manufacturers the right to put any conditions on offers of 340B pricing on covered outpatient drugs bought by covered entities.
The third judge on the panel, meanwhile, asked questions that could suggest she is uncertain if the lower court ruling before the panel was final and thus ripe for review.
Two of three judges on a federal appeals court panel strongly indicated this morning that they reject the federal government’s position that nothing in the 340B statute gives drug manufacturers the right to put any conditions on offers of 340B pricing on covered outpatient drugs bought by covered entities.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
